Researchers have been developing a multi-well microplate reader variant for use in large volume laboratory environments using NanoLogix technology. The multi-well plates have exceptionally fast live-threat results similar to standard NanoLogix technology for live cell detection and identification.
NanoLogix, a biotechnology company specializing in live cell diagnostics, and University of Texas Health Science Center – Houston (UTHSC-Houston) researchers developed the multi-well, microplate reader to detect active threat bacteria and other microorganisms faster than Flow Cytometry and traditional Petri culture methods.
Research from a recently completed clinical study using NanoLogix technology will be presented at the June meeting of the American Society for Microbiology. Dr. Jonathan Faro of UTHSC-Houston will present the research, which focuses on detection, identification, and determination of antibiotic sensitivity of Group B Streptococcus (GBS) during pregnancy.
The new data shows NanoLogix diagnostics consistently provides results in a 4 to 6 hour window, dramatically shorter than standard culturing times of 48 to 72 hours. The data and the associated clinical study narrative is currently being formatted for submission for peer-review publication, as well as to the US FDA for acceptance as a non-invasive diagnostic technology.
“These are exciting times for NanoLogix,” said CEO Bret Barnhizer. ”Our technology has the potential to dramatically affect the course of human health and events over the past eight months have greatly enhanced our position for the future.”
Research and developenthas converged to dramatically enrich NanoLogix’ bacteria and protozoa detection technology portfolio.
The detection for Tuberculosis (TB) utilizing NanoLogix’ BNF and BioNanoPore (BNP) technologies has been completed by a major independent, third-party research laboratory. Live-threat TB was detected with NanoLogix BNP technology in 4 to 5 days, as opposed to 21 to 84 days with standard culture. TB was also detected and identified with the company’s BNF technology in less than two hours. Peer-reviewed publication and FDA submittal are in process for results from both BNP and BNF Tuberculosis research.
“We are thrilled to be dramatically cutting bacterial detection times from days to hours for many pathogens,” said Barnhizer. “Specifically, we have reduced wait times for TB from weeks to days, while protozoa detection times for Cryptosporidium, which is responsible for over 50 percent of waterborne illnesses, have been cut from weeks to hours. At the same time, we have been able to accomplish these results with improved quality of detection.”
The NanoLogix BNF and BioNanoPore (BNP) technology will be on exhibit June 16th–19th at the 112th General Meeting of the American Society for Microbiology in San Francisco.